Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints Peter Theil head of non-clinical development

He joins the Belgium pharma company from Genentech

Peter Theil has joined UCB as vice president, head of non-clinical development for UCB's New Medicines research arm.

He joins the Belgium pharma company from Genentech, where he was head of early development, pharmacokinetic/pharmacodynamics sciences.

At UCB he will be part of New Medicine's leadership team and will be based in Braine, Belgium.

UCB said Theil's scientific knowledge, organisational and leadership skills would invaluable in continuing it unique emphasis and success in developing both small and large molecules.

Peter is the second new member of the New Medicines leadership team, following the recent appointment of Duncan McHale, who joined UCB as VP head of global exploratory development.

McHale moved to the company from AstraZeneca, where he was held the role of head of projects, VP personalised medicine and biomarkers.

28th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics